Novo Nordisk Swallows the Competition with Wegovy Pill Surge
Key takeaways
- It turns out that while people love the results of the "skinny jab," they love the convenience of a daily tablet even more.
- Novo Nordisk hiked its full-year profit guidance on Wednesday after a blowout first quarter.
- However, those reported numbers carry a giant asterisk.
Novo Nordisk Swallows the Competition with Wegovy Pill Surge Mark Nichols Wed, May 6, 2026 at 9:54 PM GMT+7 4 min read NVO LLY Novo Nordisk Swallows the Competition with Wegovy Pill Surge - Moby THE GIST Novo Nordisk is officially back on the offensive. After a year of being chased by rival Eli Lilly, the Danish pharmaceutical giant just posted first-quarter results that smashed expectations, largely thanks to a massive U.S. appetite for its new weight-loss pill, Wegovy.
It turns out that while people love the results of the "skinny jab," they love the convenience of a daily tablet even more.
Novo Nordisk hiked its full-year profit guidance on Wednesday after a blowout first quarter. On a reported basis, sales jumped 32% to reach 96.8 billion Danish kroner ($15.2 billion), while operating profit surged 65% to 59.6 billion kroner.